[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Samuels AL, Peeva VK, Papa RA, Firth MJ, Francis RW, Beesley AH, Lock RB, Kees UR: Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia. BMC Genomics; 2010;11:256
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.
  • BACKGROUND: Pre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms.
  • For haematological malignancies, the non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse is one of the most successful models to study paediatric acute lymphoblastic leukaemia (ALL).
  • However, for this model to be effective for studying engraftment and therapy responses at the whole genome level, careful molecular characterisation is essential.
  • Using the human Affymetrix whole transcript platform we analysed transcriptional profiles from engrafted tissues without prior cell separation of mouse cells and found it to return highly reproducible profiles in xenografts from individual mice.
  • Importantly, this masking approach can be applied and adapted to other xenograft models where human tissue infiltration is lower.
  • This model provides a powerful platform for identifying genes and pathways associated with ALL disease progression and response to therapy in vivo.
  • [MeSH-major] Disease Models, Animal. Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Animals. Bone Marrow / metabolism. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Species Specificity. Spleen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Br J Cancer. 2009 Jun 16;100(12):1926-36 [19436302.001]
  • [Cites] Stem Cells. 2001;19(5):443-52 [11553853.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4100-8 [12010813.001]
  • [Cites] Genome Biol. 2003;4(7):R46 [12844362.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):837-44 [15120039.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1597-600 [2595371.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):161-5 [15688078.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):119-29 [15798092.001]
  • [Cites] Nucleic Acids Res. 2005;33(13):e111 [16030348.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):617-28 [16728587.001]
  • [Cites] BMC Cancer. 2006;6:229 [17002788.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1731-7 [17041637.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):32-40 [17210681.001]
  • [Cites] Br J Haematol. 2007 May;137(4):319-28 [17456054.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):740-8 [17760805.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Clin Exp Metastasis. 2008;25(1):81-8 [17932773.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):656-64 [18302714.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] Curr Pharm Des. 2008;14(21):2023-39 [18691113.001]
  • [Cites] Exp Hematol. 2001 Mar;29(3):322-9 [11274760.001]
  • (PMID = 20406497.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2876122
  •  go-up   go-down


2. Ma MC, Wang MC, Pei SN, Kuo CY: Hepatosplenic fungal infection in adult patients with acute leukemia. Chang Gung Med J; 2008 Jan-Feb;31(1):74-80
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 2001 to 2004, 163 adult patients were diagnosed with acute leukemia at our center: 41 patients had acute lymphoblastic leukemia (ALL) and 122 patients had acute myeloid leukemia (AML).
  • RESULTS: Of these 163 patients, 16 patients (9.8%) developed hepatosplenic fungal infection: three were ALL patients and 13 were AML patients.
  • All of these patients suffered from febrile neutropenia after chemotherapy.
  • The most common infection sites found by computed tomography were the spleen (94%) and the liver (88%).
  • CONCLUSION: Alkaline phosphatase level and computed tomography are useful tools for the diagnosis of hepatosplenic fungal infection.
  • Infection-related mortality is very low with effective treatment.
  • Treatment for underlying diseases should proceed as soon as possible if the infection has been controlled.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Liver Diseases / etiology. Mycoses / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Antifungal Agents / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419056.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


3. Hsiao HH, Tsai HJ, Liu YC, Tseng YT, Lu PL, Yang WC, Liu TC, Lin SF: Invasive fungal infections in patients with acute leukemia. Kaohsiung J Med Sci; 2006 May;22(5):217-22
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such infections may hinder additional treatment, especially for patients with leukemia.
  • A total of 18 patients were enrolled in the study: 12 had microabscesses of the liver and/or spleen and/or kidneys; four had sinonasal infections; and two had pulmonary infections.
  • Most of the patients (88.9%) received amphotericin B during treatment for fungal infection.
  • In the study, there were 11 mortalities, including five patients who died during therapy and six who later died as a result of relapse or refractoriness of the leukemia.
  • We suggest that many patients may have a good response to antifungal therapy, and that fungal infection does not have to preclude additional chemotherapy after proper management.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Mycoses / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793556.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Herst PM, Davis JE, Neeson P, Berridge MV, Ritchie DS: The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica; 2009 Jul;94(7):928-34
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.
  • BACKGROUND: The redox-active isoflavene anti-cancer drug, phenoxodiol, has previously been shown to inhibit plasma membrane electron transport and cell proliferation and promote apoptosis in a range of cancer cell lines and in anti-CD3/anti-CD28-activated murine splenocytes but not in non-transformed WI-38 cells and human umbilical vein endothelial cells.
  • In addition, we evaluated the effect of phenoxodiol on the viability of leukemic cell lines and primary myeloid and lymphoid leukemic blasts.
  • RESULTS: We demonstrated that phenoxodiol inhibited plasma membrane electron transport and cell proliferation (IC(50) 46 microM and 5.4 microM, respectively) and promoted apoptosis of rapidly proliferating human T cells but did not affect resting T cells.
  • CONCLUSIONS: The ability of phenoxodiol to kill rapidly proliferating lymphocytes makes this drug a promising candidate for the treatment of pathologically-activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as auto-immune diseases and graft-versus-host disease.
  • [MeSH-major] Isoflavones / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Membrane / metabolism. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Humans. Mice. Oxidation-Reduction. Spleen / cytology. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Umbilical Veins / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):913-23 [17158952.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):895-904 [17168740.001]
  • [Cites] Biochim Biophys Acta. 2007 Feb;1767(2):170-7 [17266920.001]
  • [Cites] J Immunol Methods. 2007 Apr 10;321(1-2):196-9 [17306826.001]
  • [Cites] Oncol Res. 2007;16(7):299-312 [17518268.001]
  • [Cites] BMC Neurosci. 2007;8:61 [17672914.001]
  • [Cites] Biochem Pharmacol. 2007 Dec 3;74(11):1587-95 [17904534.001]
  • [Cites] Antioxid Redox Signal. 2000 Summer;2(2):231-42 [11229528.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2581-5 [12529967.001]
  • [Cites] Eur J Cancer. 2003 May;39(7):1012-8 [12706372.001]
  • [Cites] Methods Mol Med. 2003;81:377-94 [12725132.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2611-20 [12730675.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1656(2-3):79-87 [15178469.001]
  • [Cites] Science. 1989 Oct 27;246(4929):500-3 [2814477.001]
  • [Cites] Oncol Res. 2004;14(11-12):567-78 [15666998.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3364-73 [15833870.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 1;1708(1):108-19 [15882838.001]
  • [Cites] Biotechnol Annu Rev. 2005;11:127-52 [16216776.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):599-608 [16388521.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2412-20 [16353157.001]
  • [Cites] Ann Oncol. 2006 May;17(5):860-5 [16524966.001]
  • [Cites] Curr Opin Investig Drugs. 2006 Jun;7(6):542-8 [16784025.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):427-33 [16463060.001]
  • [Cites] Biofactors. 2005;25(1-4):43-60 [16873929.001]
  • [Cites] Anticancer Drugs. 2006 Nov;17(10):1151-61 [17075314.001]
  • [Cites] J Transl Med. 2007;5:6 [17257402.001]
  • (PMID = 19535345.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Isoflavones; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 995FT1W541 / phenoxodiol
  • [Other-IDs] NLM/ PMC2704303
  •  go-up   go-down


5. Felice MS, Zubizarreta PA, Alfaro EM, Sackmann-Muriel F: Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol; 2001 Oct;23(7):411-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
  • PURPOSE: To assess the value of initial peripheral blast count in patients with acute lymphoblastic leukemia (ALL) and prednisone good response (PGR).
  • In the PGR group, patients were divided into two subgroups: patients who had less than 1,000 blasts/microL at diagnosis and those with at least 1,000 blasts/microL at diagnosis.
  • The authors compared the clinical and laboratory characteristics of these subgroups at diagnosis and outcome and detected significant differences in white cell count, incidence of T immunophenotype, and presence of mediastinal or spleen enlargement.
  • However, there were no differences in response to induction treatment, death in complete remission, relapses, or event-free survival probability.
  • The PGR group with an initial blast count of at least 1,000/microL had significantly higher white cell counts.
  • T markers, and mediastinal or spleen enlargement at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Infant. Leukocyte Count. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11878573.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ: CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia; 2007 Jun;21(6):1249-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
  • The role of CXCL12 in the bone marrow (BM) homing and growth of B-cell progenitor acute lymphoblastic leukemia (ALL) has been established.
  • Considering the inhibitory effect of stromal layers on the activity of chemotherapeutic agents and the interactive effect of CXCL12 antagonists with chemotherapeutic agents in vitro, this raises the possibility of using these agents to potentiate the effects of current chemotherapy regimens.
  • [MeSH-major] Chemotaxis / drug effects. Neoplastic Cells, Circulating / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, CXCR4 / antagonists & inhibitors
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Blood. Chemokine CXCL12. Chemokines, CXC / antagonists & inhibitors. Child. Child, Preschool. Disease Models, Animal. Drug Interactions. Female. Graft Survival / drug effects. Humans. Infant. Male. Mice. Neoplasm Transplantation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Spleen. Stromal Cells. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410186.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Receptors, CXCR4
  •  go-up   go-down


7. Crazzolara R, Bernhard D: CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia. Leuk Lymphoma; 2005 Nov;46(11):1545-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a malignancy with the potential to infiltrate the liver, spleen, lymph nodes and brain.
  • Because overexpression of CXCR4 on ALL cells is associated with high extramedullary organ infiltration and shorter disease-free survival, numerous pharmacological agents affecting CXCR4 have currently been investigated.
  • Wider recognition of the role of CXCR4 in ALL and manipulation of this important mechanism may lead to novel approaches in the treatment and outcome of this disease.
  • [MeSH-major] Histone Deacetylase Inhibitors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, CXCR4 / physiology
  • [MeSH-minor] Down-Regulation / drug effects. Enzyme Inhibitors / therapeutic use. Humans. Leukemic Infiltration / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236608.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Receptors, CXCR4
  • [Number-of-references] 41
  •  go-up   go-down


8. Handa H, Motohashi S, Isozumi K, Komatsumoto S, Nara M: CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside. Acta Haematol; 2002;108(1):47-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
  • He died of sepsis due to severe neutropenia after the third course of chemotherapy.
  • His autopsy revealed blast infiltration in the lymph nodes, liver, spleen and vertebral bone marrow.
  • Recently, CD7+ and CD56+ myeloid/natural killer precursor acute leukemia has been associated with a poor prognosis.
  • Our case illustrates that myeloid/natural killer cell precursor acute leukemia shows some response to intensive chemotherapy for acute myeloid leukemia, but such therapy is insufficient to effect a cure.
  • To overcome the resistance of this disease to chemotherapy, further studies should explore other treatment strategies.
  • [MeSH-major] Antigens, CD56 / analysis. Antigens, CD7 / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / analogs & derivatives. Killer Cells, Natural / pathology. Leukemia, Myeloid / drug therapy. Myeloid Cells / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acute Disease. Aged. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Daunorubicin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Fatal Outcome. Humans. Idarubicin / administration & dosage. Leukemic Infiltration. Lymphoma, Non-Hodgkin / diagnosis. Male. Mitoxantrone / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sarcoma, Myeloid / diagnosis. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12145468.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 9YVR68W306 / enocitabine; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Guo Y, Xue Y, Xie X, Lu D, Geng M: [Chromosome t (4; 11) acute lymphoblastic leukemia: an analysis of 10 cases]. Zhonghua Xue Ye Xue Za Zhi; 2000 Feb;21(2):71-3
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chromosome t (4; 11) acute lymphoblastic leukemia: an analysis of 10 cases].
  • OBJECTIVE: To characterize morphologically, immunophenotypically, cytogenetically and clinically the acute lymphoblastic leukemia (ALL) with t (4;.
  • The patients were treated with combination chemotherapy of DOPL or VP regimen.
  • Liver, spleen and/or lymph nodes were involved in all. t (4;.
  • 11) ALL were B cell origin.
  • Median survival time was 5.5 months in the present series.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Chromosome 10.
  • Genetic Alliance. consumer health - Chromosome 11.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11876961.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Badowska W: [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1001-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
  • AIM: Analysis of treatment outcome and identification of prognostic factors in children treated for acute lymphoblastic leukaemia (ALL).
  • Probability of event-free survival (pEFS) was the principal indicator of effective of treatment in ALL.
  • The analysis of treatment results showed gradual improvement in the consecutive treatment protocols, including: pEFS=0.61+/-0.15 in the New York protocol; in the New York II - pEFS=0.76+/-0.15; in ALL-BFM-86 - pEFS=0,71+/-0,10; in ALL-BFM-90 - pEFS=0.79+/-0.08; in ALL-BFM-95 - pEFS=0.72+/-0.11.
  • Prognostic factors for pEFS by univariate analysis were: male gender (p=0.003), age under 2 year (p=0.004), spleen enlargement (p=0.043), Hgb>10g/dl (p=0.025), WBC>100 G/L (p=0.007), FAB L2 (p<0.001), loss of weight p=0.022 and defects of eyesight (p=0.006) before the diagnosis of ALL, and HBV infection during the therapy (p=0.019).
  • Independent risk factors by multivariate analysis were: male gender (p=0.005), age under 2 year (p=0.052), the spleen enlargement (p=0.028), WBC>100 G/L (p=0.007), FAB L2 (p=0.007), eyesight defects (p=0.009) before the diagnosis of ALL, and infection of HBV during the therapy (p=0.027).
  • CONCLUSIONS: Large progress has been made in the treatment of acute lymphoblastic leukaemia of childhood and adolescence over the analyzed period of 17 years.
  • Treatment results for children with acute lymphoblastic leukaemia in Olsztyn Province are similar to the results in the Polish Paediatric Leukaemia/Lymphoma Study Group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Infant. Male. Methotrexate / therapeutic use. Poland / epidemiology. Prednisone / therapeutic use. Prevalence. Prognosis. Sex Factors. Thioguanine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531816.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; New York protocol; PVDA protocol
  •  go-up   go-down


11. Ng SM, Ariffin WA, Lin HP, Chan LL, Chin YM: Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr; 2000 Apr;46(2):73-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children.
  • The purpose of the study was to evaluate the incidence of myeloid antigen coexpression and its prognostic significance in childhood acute lymphoblastic leukemia (ALL) in Malaysia.
  • Presenting features and treatment outcome of 39 B-lineage ALL patients with myeloid antigen coexpression (My+B) were compared with 112 B-lineage ALL patients without myeloid antigen coexpression (My-B) for similarity in demographic, clinical and laboratory features and their treatment outcome.
  • My+B and My-B patients were treated with a uniform treatment protocol.
  • Univariate analyses showed that presenting features were similar between My+B and My-B with regard to age, sex, race, FAB morphology, white cell count, hemoglobin level, platelet count, liver/spleen size, central nervous system or mediastinal involvement, presence of lymphadenopathy, and proportion of blast cells detected in the marrow.
  • Treatment outcome were not significant between the two groups.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antigen Presentation / drug effects. B-Lymphocytes / classification. B-Lymphocytes / immunology. Biomarkers / analysis. Cell Lineage. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunophenotyping. Infant. Male. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10822932.001).
  • [ISSN] 0142-6338
  • [Journal-full-title] Journal of tropical pediatrics
  • [ISO-abbreviation] J. Trop. Pediatr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers
  •  go-up   go-down


12. Attarbaschi A, Mann G, Dworzak M, Urban C, Fink FM, Dieckmann K, Riehm H, Gadner H, Austrian Cooperative Study Group: Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. Wien Klin Wochenschr; 2002 Feb 28;114(4):148-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
  • Between 1981 and 1999, 890 Austrian children with acute lymphoblastic leukemia (ALL) were treated in 5 consecutive trials using protocols from the Berlin-Frankfurt-Münster (BFM) Group.
  • In the trials BFM-A (Austria) 81 and ALL A 84, treatment stratification was performed using a risk factor, which was calculated from the initial peripheral blast cell count, and size of liver and spleen.
  • In the following studies (BFM-A 86, 90 and 95) early response to a 7-day systemic mono-therapy with prednisone (as measured by the peripheral blast cell count) was used as an overriding stratification factor; in order to reduce the need for cranial radiotherapy, all patients received high-dose methotrexate (5 g/m2) for preventive central nervous system treatment.
  • Furthermore, conventional risk factors such as leukocyte count and age at time of diagnosis, could not be used to indicate patients in the low and intermediate risk group who might eventually relapse.
  • Thus, in trial BFM-A 2000, detection of minimal residual disease by polymerase chain reaction-based methods after 5 and 12 weeks of therapy was introduced for treatment stratification.
  • Minimal residual disease was prospectively shown to predict relapses more precisely and, as a matter of fact, may allow a more exact definition of which patients are at risk and which patients belong to the subgroup with a good prognosis despite reduced treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Austria. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Multicenter Studies as Topic. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Prognosis. Retrospective Studies. Risk

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2002 Feb 28;114(4):141-2 [12060979.001]
  • (PMID = 12060981.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


13. Ng SM, Lin HP, Ariffin WA, Zainab AK, Lam SK, Chan LL: Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol. J Trop Pediatr; 2000 Dec;46(6):338-43
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol.
  • The presenting features and treatment outcome for 575 Malaysian children (< or = 12 years of age) with newly diagnosed acute lymphoblastic leukemia (ALL), admitted to the University Hospital, Kuala Lumpur, Malaysia between 1 January 1980 and 30 May 1995 were evaluated to determine their prognostic significance.
  • All except 10 patients, with identified French-American-British L3 morphology were treated with the modified Berlin-Frankfurt-Munster 78 treatment protocol.
  • Univariate analyses of failure rate conferred age, sex, white cell count and hemoglobin level as potentially significant prognostic factors.
  • Race, platelet count, morphological subtype, liver/spleen size, lymphadenopathy, central nervous system and mediastinal mass involvement did not show any significant effect on treatment outcome.
  • The 2-year survival rate was significantly different with regard to age, white cell count and hemoglobin level.
  • These prognostic factors may have implications on future stratification of risk-adjusted initial treatment in the management of childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemoglobins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Age Factors. Child. Child, Preschool. Clinical Protocols. Female. Humans. Infant. Leukocyte Count. Male. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11191144.001).
  • [ISSN] 0142-6338
  • [Journal-full-title] Journal of tropical pediatrics
  • [ISO-abbreviation] J. Trop. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


14. Moisă SM, Rusu A, Dumitraş S, Burlea M, Miron I: [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital]. Rev Med Chir Soc Med Nat Iasi; 2008 Apr-Jun;112(2):356-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital].
  • The goals of this paper were to study the various types of digestive disease in acute lymphoblastic leukemia (ALL), to characterize the children in the study group by age, sex and environment, by presence of liver and spleen enlargement, levels of GOT, GPT, vomiting, to evaluate methotrexate (MTX) serum levels al 24 hours and 48 hours after administration, and to analyze the correlation between MTX levels and MTX liver and blood toxicity.
  • MATERIAL AND METHOD: We studied 39 immunocompromised children hospitalized in the IV-th Pediatric Clinic-Oncology Ward, between 1983-2005, with acute lymphoblastic leukemia (ALL); most of them exhibited defects of humoral immunity such as transitory hypogammaglobulinemia, and defects of the cellular immunity that accompanied hepatomegaly, hepatic cytolysis and biliary obstruction.
  • RESULTS: The diagnostic of ALL was sustained by: medullar biopsy, lumbar punction, cytochemical reactions, blood cell count, flow-cytometry, methotrexate level determination.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / blood. Drug-Induced Liver Injury. Immunocompromised Host. Leucovorin / therapeutic use. Methotrexate / adverse effects. Methotrexate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vitamin B Complex / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Digestive System Diseases / chemically induced. Drug Therapy, Combination. Female. Hospitals, Pediatric. Hospitals, University. Humans. Infant. Infant, Newborn. Liver Diseases / prevention & control. Male. Oncology Service, Hospital. Retrospective Studies. Romania. Treatment Outcome. Vomiting / chemically induced. Vomiting / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295004.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Kabir A, Begum M: Prognostic factors analysis in a therapeutic trail of acute lymphoblastic leukaemia (ALL). Bangladesh Med Res Counc Bull; 2002 Apr;28(1):19-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors analysis in a therapeutic trail of acute lymphoblastic leukaemia (ALL).
  • It is common practice in therapeutic trials in Acute Lymphoblastic Leukaemia (ALL) to analyse the impact of prognostic factors on clinical outcome.
  • Prognostic factors analysed include age, sex, lymphomatous presentations (bulky peripheral lymphadenopathy, mediastinal mass and enlargement of spleen and liver), initial leucocyte count, blast cell morphology and bone marrow response to chemotherapy.
  • Remission induction and maintenance therapy with conventional combination chemotherapy and CNS prophylaxis with intra thecal methotrexate and radiotherapy were instituted to all patients for long term event free survival.
  • Results of induction therapy and overall outcomes of treatment were observed.
  • 3 patients (10%) failed to go into remission after 12 weeks of therapy.
  • Among 27 patients those obtained remission, 17 patients continued event (failure to remit, relapse and death) free survival, 7 patients suffered relapse of their leukaemia and 3 patients died during maintenance therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12587757.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


16. Golay J, Di Gaetano N, Amico D, Cittera E, Barbui AM, Giavazzi R, Biondi A, Rambaldi A, Introna M: Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol; 2005 Feb;128(3):310-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
  • Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid leukaemia.
  • As approximately 18% of acute lymphoblastic leukaemias (ALL) are also CD33 positive, we have investigated the cytotoxic activity of GO on CD33+ ALL cells in vitro and in vivo.
  • 10 ng/ml GO induced 30-95% inhibition of thymidine uptake and 30-70% cell death in four freshly isolated and one in vivo passaged CD33+ ALL-cell cultures.
  • 5 x 10(6) ALL-2 cells inoculated in the tail vein of severe combined immunodeficient mice engrafted into haematopoietic organs, reaching a mean of 70%, 61% and 69% human CD45+ cells in bone marrow, spleen and liver, respectively, at 35 d.
  • To test the therapeutic activity of GO, 50 or 100 microg immunotoxin was inoculated i.p. on days 7, 11 and 15 following tumour-cell inoculation.
  • GO treatment dramatically inhibited expansion of ALL-2 cells in all tested organs and increased survival of tumour-injected animals by 28-41 d, relative to controls.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Immunotoxins / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Cell Death / drug effects. Female. Humans. Immunophenotyping. Mice. Mice, SCID. Neoplasm Transplantation. Sialic Acid Binding Ig-like Lectin 3. Transplantation, Heterologous. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667532.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Cd33 protein, mouse; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


17. Godt C, Regnery A, Schwarze B, Junker K, Porschen R: A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD). Z Gastroenterol; 2009 Mar;47(3):283-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had received a bone marrow transplant two years previously for an acute lymphocytic leukaemia of B-cell origin.
  • Further investigations revealed a diffuse infiltration of the liver, spleen, both kidneys and lungs.
  • Histologically, a monomorphic post-transplant lymphoproliferative disorder was diagnosed, the subtype was a high grade diffuse-large cell Non-Hodgkin's lymphoma of B-cell origin.
  • The current therapeutic approach to the subtype of PTLD we saw in this patient is CHOP chemotherapy, comprising the anti-CD 20 antibody rituximab if CD 20-positivity is present.
  • This patient had a fatal course of the disease and died a few days after the first chemotherapy cycle due to severe multiple organ failure.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Colitis, Ulcerative / etiology. Colorectal Neoplasms / diagnosis. Diarrhea / etiology. Gastrointestinal Hemorrhage / etiology. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


18. Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, Rattat D, Buck A, Döhner H, Reske SN: Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm; 2002 Apr;17(2):151-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
  • BACKGROUND: Stem cell transplantation (SCT) is potentially curative for high-risk leukemia patients.
  • Conditioning regimens affect relapse rate and treatment-related mortality.
  • Standard conditioning consisted of high-dose chemotherapy and 12 Gy total-body irradiation.
  • Forty-six patients received allogenic, and four received autologous, stem cell grafts.
  • RESULTS: The mean radiation absorbed doses (in Gy) were: marrow, 13.9 +/- 4.6; liver, 5.7 +/- 2.7; spleen, 22.6 +/- 25.5; kidneys, 6.8 +/- 2.6; lungs, 0.8 +/- 0.7; total body, 1.4 +/- 0.3.
  • The tumor-to-organ-ratios were 2.4 for liver, 0.6 for the spleen, 2.0 for the kidneys and 17.8 for the lungs.
  • Type of leukemia did not affect radiation absorbed doses of marrow, lungs, kidneys and liver.
  • Mean marrow dose of transplanted patients in complete remission was 1.37 +/- 0.43 Gy/GBq, compared with 1.34 +/- 0.29 Gy/GBq for patients with leukemic blast marrow infiltration of 5-25%.
  • Another 13 patients (7%) died of treatment-related causes.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antigens, CD / immunology. Antigens, Differentiation / immunology. Hematopoietic Stem Cell Transplantation. Leukemia / metabolism. Leukemia / therapy. Radioimmunotherapy. Rhenium / pharmacokinetics. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / immunology. Bone Marrow / radiation effects. Cell Adhesion Molecules. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radionuclide imaging. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / radionuclide imaging. Leukemia, Myeloid / therapy. Liver / metabolism. Liver / radiation effects. Lung / metabolism. Lung / radiation effects. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radionuclide imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiation Dosage. Radioisotopes / adverse effects. Radioisotopes / pharmacokinetics. Radioisotopes / therapeutic use. Survival Rate. Tissue Distribution

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12030109.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Radioisotopes; 7440-15-5 / Rhenium
  •  go-up   go-down


19. Herget GW, Riede UN, Schmitt-Gräff A, Lübbert M, Neumann-Haefelin D, Köhler G: Generalized herpes simplex virus infection in an immunocompromised patient--report of a case and review of the literature. Pathol Res Pract; 2005;201(2):123-9
MedlinePlus Health Information. consumer health - Herpes Simplex.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with immunodeficiency or treatment-related immunosuppression are at an increased risk of developing severe herpes simplex virus (HSV) infection.
  • We present a fatal case of a generalized HSV-1 infection in a 22-year-old female afflicted by acute lymphoblastic leukemia who was treated with polychemotherapy.
  • Punctuated areas of yellow-tan necrosis with hyperemic rims were detected in the liver, spleen, and lung.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Simplexvirus / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901133.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Cole PD, Zebala JA, Alcaraz MJ, Smith AK, Tan J, Kamen BA: Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. Cancer Chemother Pharmacol; 2006 Jun;57(6):826-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.
  • We compared the pharmacodynamic properties of AMT (given orally at 4 mg/m2 in two divided doses per week) and MTX (100 mg/m2 in four divided doses per week) among children with acute lymphoblastic leukemia.
  • To confirm these clinical observations, mice were treated four weekly injections of AMT or MTX, at a 1:20 dosage ratio, and tissue antifolate content was then determined over the subsequent 22 days.
  • We confirm the selective exclusion of AMT from the CNS compartment, while showing equivalent accumulation of AMT and MTX in the RBCs, liver, spleen, kidneys and testes.
  • Finally, we demonstrate that AMT, MTX, and their predominant polyglutamate species are equipotent inhibitors of their target intracellular enzyme dihydrofolate reductase, emphasizing the critical nature of steady-state tissue accumulation in determining the relative cytotoxic potency of these two antifolates.
  • [MeSH-major] Aminopterin / pharmacokinetics. Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Folic Acid Antagonists / pharmacokinetics. Methotrexate / pharmacokinetics
  • [MeSH-minor] Animals. Child. Child, Preschool. Erythrocytes / metabolism. Humans. Infant. Male. Mice. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tetrahydrofolate Dehydrogenase / metabolism. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Chemother Pharmacol. 2006 Sep;58(3):418. Zebala, John A [added]
  • (PMID = 16170572.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-001832-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; JYB41CTM2Q / Aminopterin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement